MedPage Today) -- A pembrolizumab (Keytruda) combination led to an overall survival (OS) boost in patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer, according to results from the KEYNOTE-A18 trial...
.png)
4990 Ash Street, Dallas, Texas 75207 972-815-7120
972-815-7120
admin@finhub.com
Copyright © 2024 finance. All Rights Reserved
